ArticleMicrobiology spectrum2025
The rise in domestic shigellosis and the genomic characteristics of
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The natural history of the emergence of sexually transmissible shigellosis.Microbial genomics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Since 2015, Taiwan has experienced a notable rise in domestic shigellosis cases, particularly among young adult males. In this study, we aimed to investigate this epidemiological trend through demographic analysis and genomic characterization of bacterial isolates. We analyzed demographic data on shigellosis cases from 2003-2014 to 2015-2022. For cases from 2015-2022, we conducted genomic analyses of IMPORTANCE: The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Shigella strains poses a growing global health threat, particularly among high-risk groups such as men who have sex with men (MSM). This study highlights the increasing prevalence of domestic shigellosis in Taiwan from 2015 to 2022, driven by the emergence of three MDR Shigella clones. These MSM-associated clones exhibit significantly higher resistance to azithromycin, extended-spectrum cephalosporins (ESCs), and ciprofloxacin compared to non-MSM-associated clones. Additionally, 14 extensively drug-resistant isolates were identified, carrying resistance genes for azithromycin and ESCs on IncFII or IncB/O/K/Z plasmids. Genomic analysis reveals that ciprofloxacin-resistant Shigella flexneri 2a (CipR_SF2) has become the most dominant clone, responsible for the majority of shigellosis cases since 2018, and is genetically distinct from strains observed in MSM-related outbreaks in other countries. By elucidating these clones' genetic characteristics and epidemiological trends, this research offers essential data for public health surveillance, helping to inform strategies for controlling the spread of MDR and XDR Shigella infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.